NASDAQ
Replimune Group, Inc. (REPL)
♥ 631 Thanks from members
Replimune Group, Inc. (REPL) exhibits strong bullish momentum driven by the FDA accelerated approval of TUDRIQEV (RP1) for advanced cutaneous melanoma, offset by historical volatility, recent insider tax-withholding stock sales, and necessary confirmatory trials.